S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Biden's pick to lead FAA withdraws amid shaky Senate support
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Travel disruption hits Germany on eve of transport strike
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Biden's pick to lead FAA withdraws amid shaky Senate support
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Travel disruption hits Germany on eve of transport strike
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Biden's pick to lead FAA withdraws amid shaky Senate support
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Travel disruption hits Germany on eve of transport strike
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Technical issues at Lufthansa cause delays in Frankfurt
S&P 500   3,970.99
DOW   32,237.53
QQQ   310.89
Ukraine demands emergency UN meeting over Putin nuclear plan
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
New Russian campaign tries to entice men to fight in Ukraine
Biden's pick to lead FAA withdraws amid shaky Senate support
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Travel disruption hits Germany on eve of transport strike
Factory or farm? Oregon may alter land use for chipmakers
[BREAKING] New "Living Missile" to Replace Nuclear Missiles (Ad)
Adele extends Las Vegas residency, plans concert film
Technical issues at Lufthansa cause delays in Frankfurt
NASDAQ:BLTE

Belite Bio - BLTE Stock Forecast, Price & News

$27.01
+0.13 (+0.48%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$27.00
$28.00
50-Day Range
$25.61
$33.50
52-Week Range
$8.80
$44.70
Volume
17,109 shs
Average Volume
13,908 shs
Market Capitalization
$672.55 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.50

Belite Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
112.9% Upside
$57.50 Price Target
Short Interest
Healthy
0.16% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.93mentions of Belite Bio in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

199th out of 1,005 stocks

Pharmaceutical Preparations Industry

83rd out of 486 stocks


BLTE stock logo

About Belite Bio (NASDAQ:BLTE) Stock

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Stock News Headlines

Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase
Belite Bio Inc. ADR
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Belite Bio initiated with a Buy at Benchmark
Belite Bio Inc ADR - Stock Quote BLTE
Belite Bio Inc ADR (BLTE)
See More Headlines
Receive BLTE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Belite Bio and its competitors with MarketBeat's FREE daily newsletter.

BLTE Company Calendar

Today
3/26/2023
Next Earnings (Estimated)
5/05/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLTE
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$57.50
High Stock Price Forecast
$58.00
Low Stock Price Forecast
$57.00
Forecasted Upside/Downside
+112.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
21,590,000
Market Cap
$672.55 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. Yu-Hsin Lin M.B.A. (Age 45)
    Ph.D., Chairman of Directors & CEO
  • Mr. Hao-Yuan Chuang C.F.A. (Age 39)
    F.R.M., M.B.A., CFO & Director
  • Dr. Nathan L. Mata Ph.D. (Age 57)
    Chief Scientific Officer
  • Ms. Ching-Chen Chiu M.Sc. (Age 53)
    VP of Clinical Operations













BLTE Stock - Frequently Asked Questions

Should I buy or sell Belite Bio stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Belite Bio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BLTE shares.
View BLTE analyst ratings
or view top-rated stocks.

What is Belite Bio's stock price forecast for 2023?

2 equities research analysts have issued 12 month target prices for Belite Bio's shares. Their BLTE share price forecasts range from $57.00 to $58.00. On average, they expect the company's stock price to reach $57.50 in the next year. This suggests a possible upside of 112.9% from the stock's current price.
View analysts price targets for BLTE
or view top-rated stocks among Wall Street analysts.

How have BLTE shares performed in 2023?

Belite Bio's stock was trading at $30.1450 on January 1st, 2023. Since then, BLTE shares have decreased by 10.4% and is now trading at $27.01.
View the best growth stocks for 2023 here
.

When is Belite Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 5th 2023.
View our BLTE earnings forecast
.

What ETF holds Belite Bio's stock ?

ALPS Medical Breakthroughs ETF holds 16,217 shares of BLTE stock, representing 0.49% of its portfolio.

When did Belite Bio IPO?

(BLTE) raised $36 million in an IPO on Friday, April 29th 2022. The company issued 6,000,000 shares at a price of $5.50-$6.50 per share.

What is Belite Bio's stock symbol?

Belite Bio trades on the NASDAQ under the ticker symbol "BLTE."

Who are Belite Bio's major shareholders?

Belite Bio's stock is owned by a number of institutional and retail investors. Top institutional investors include Atria Wealth Solutions Inc. (3.26%), Alps Advisors Inc. (0.06%), UBS Group AG (0.02%) and Morgan Stanley (0.01%).

How do I buy shares of Belite Bio?

Shares of BLTE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Belite Bio's stock price today?

One share of BLTE stock can currently be purchased for approximately $27.01.

How much money does Belite Bio make?

Belite Bio (NASDAQ:BLTE) has a market capitalization of $672.55 million.

How can I contact Belite Bio?

The official website for the company is belitebio.com. The company can be reached via phone at 858-246-6240 or via email at ir@belitebio.com.

This page (NASDAQ:BLTE) was last updated on 3/26/2023 by MarketBeat.com Staff